Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

The 7 Biggest Investment Mistakes to Avoid in 2023

By Josh Enomoto, InvestorPlace Contributor

Although market participants may be eager to make up for 2022’s losses, be aware of the investment mistakes to avoid in 2023.

NVAX Stock Alert: What to Know as Novavax Names New CEO

By Josh Enomoto, InvestorPlace Contributor

Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries.

7 Must-Buy Value Stocks for Your January Buy List

By Josh Enomoto, InvestorPlace Contributor

Although the troubles of 2022 splashed red ink on investors’ portfolios, this development also bodes well for value stocks to buy.

7 Must-Buy Blue-Chip Stocks for Your January Buy List

By Josh Enomoto, InvestorPlace Contributor

Although 2022 produced some rough moments for investors, the new year brings discounts in blue-chip stocks to buy.

7 Must-Buy Tech Stocks for Your January Buy List

By Josh Enomoto, InvestorPlace Contributor

Although many investors received a brutal beatdown in 2022, the discount also opens doors for compelling tech stocks to buy.

CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines

By Josh Enomoto, InvestorPlace Contributor

CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock.

CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal

By Josh Enomoto, InvestorPlace Contributor

CytomX Therapeutics announced a licensing deal with Moderna, which may supercharge the underlying ambitions of CTMX stock.

The 7 Best Stocks Under $15 to Buy Now

By Josh Enomoto, InvestorPlace Contributor

Undervalued and underappreciated, the best stocks under $15 have the potential to deliver outsized returns over the medium to long term.

What Meta Platforms’ $414 Million E.U. Fine Means for META Stock

By Josh Enomoto, InvestorPlace Contributor

Regulators from the E.U. imposed a $414 million fine on Meta Platforms, creating significant challenges for META stock.

Vimeo (VMEO) Stock Falls on Plans to Lay Off 11% of Staff

By Josh Enomoto, InvestorPlace Contributor

Vimeo recently announced layoffs that will impact 11% of its workforce, raising major concerns over embattled VMEO stock.

Load More